AFEEZA SANTAMARIA: Open Payments
NPI 1922796937 · LEDGEWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,025 in 53 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $57 · 2025 $1,025
Food & beverage: $1,025
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $261 |
| ABBVIE INC. | 16 | $170 |
| Lilly USA, LLC | 5 | $101 |
| AstraZeneca Pharmaceuticals LP | 4 | $97 |
| Amgen Inc. | 3 | $64 |
| PFIZER INC. | 2 | $57 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $53 |
| IBSA Pharma Inc. | 2 | $46 |
| Abbott Laboratories | 2 | $40 |
| Exact Sciences Corporation | 2 | $37 |
Products named: MOUNJARO, QULIPTA, Ozempic, Wegovy, VRAYLAR, NURTEC ODT, Kerendia, BREZTRI.
Industry payments across NJ — which companies pay providers there.
